Gene Study for Leprosy Prognosis
Part of Infections clinical trials.
This study looks at whether a specific gene (Rab 32) affects how leprosy progresses. It may help doctors better predict outcomes for people with leprosy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed positive skin smear test for the bacteria that causes leprosy.
- You cannot be allergic to sulfa drugs (a type of antibiotic).
- You cannot be allergic to clofazimine or rifampin (medications used for leprosy).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This study looks at people with Hansen's disease (leprosy) in Costa Rica to understand how it affects them and how it's treated. By joining, you help researchers learn more about this condition to improve care for others.
This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
This study looks at a gene that may be linked to lupus. It aims to understand how this gene affects the disease, which could help improve future treatments.
This study looks at how tuberculosis bacteria become resistant to drugs. If you have tested positive for TB, this study might help find better treatments for resistant TB.
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.